**Mankind Pharma Q3 FY26: Steady Growth Amid Market Caution** **Mankind Pharma** has reported a resilient performance for the quarter ended December 31, 2025 (Q3 FY26). The company delivered double-digit revenue growth driven by its domestic stronghold and expanding export footprint, although market reaction remained tepid due to broader execution concerns. **Financial Highlights** * **Net Profit:** Rose **8% YoY** to **Rs 414 crore**, largely in line with street expectations. * **Revenue:** Grew **11.5% YoY** to **Rs 3,567 crore**, up from Rs 3,199 crore in the same period last year. * **EBITDA:** Reported at **Rs 816 crore** with a margin of **22.9%**. Adjusted EBITDA (factoring in one-offs) stood higher at **Rs 923 crore** (25.9% margin). * **EPS:** Diluted Earnings Per Share increased **6.7%** to **Rs 9.9**. **Operational Drivers** **Domestic Dominance** The India business continues to be the primary engine, generating **Rs 3,046 crore** (up **11.1% YoY**). Growth was spearheaded by chronic therapies, particularly in the cardiac and anti-diabetic segments, where the company outperformed the wider Indian Pharmaceutical Market (IPM). **Export & Consumer Health** * **Exports:** Witnessed a sharp **14.1%** surge to **Rs 521 crore**, supported by strong traction in the international Bharat Serums and Vaccines (BSV) business. * **Consumer Healthcare:** Recovered to post **5.2% growth**, a significant improvement from the decline seen in the previous quarter. Key brands like *Manforce* and *Gas-O-Fast* showed healthy secondary sales. **Market Reaction & Sentiment** Despite the headline growth, the stock faced selling pressure, slipping approximately **4%** to trade near the **Rs 2,080 – Rs 2,155** levels following the announcement. Investors appear cautious regarding: * **Sequential Weakness:** Revenue and profit remained muted on a quarter-on-quarter basis. * **Execution Risks:** Concerns linger over the pace of organic growth in acute therapies and the integration of recent acquisitions. **Strategic Outlook** Management remains focused on consolidating the BSV acquisition and expanding its share in the chronic therapy market, which now accounts for nearly **40%** of total domestic sales. The recovery in the consumer healthcare segment and increased contribution from modern trade channels (now **13.1%** of sales) signal a stabilizing portfolio mix heading into the final quarter of FY26.